EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • June 2nd, 2023 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • Delaware
This equity purchase agreement is entered into as of June 1, 2023 (this “Agreement”), by and between AXIM Biotechnologies, Inc., a Nevada corporation (the “Company”), and Cross & Company, a Nevada corporation (the “Investor”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 7th, 2018 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • Utah
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 28, 2018 is entered into by and between AXIM BIOTECHNOLOGIES, INC., a Nevada corporation (“Company”), and ATLAS SCIENCES, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”).
AXIM BIOTECHNOLOGIES, INC. STOCK AWARD AGREEMENT UNDER AXIM BIOTECHNOLOGIES, INC. 2015 STOCK INCENTIVE PLANStock Award Agreement • June 14th, 2022 • Axim Biotechnologies, Inc. • Pharmaceutical preparations
THIS STOCK AWARD AGREEMENT (the “Agreement”) is entered into as of _________________, 20__ by and between _________________________ (hereinafter referred to as “Grantee”) and AXIM Biotechnologies, Inc. a Nevada corporation (hereinafter referred to as the “Company”), pursuant to the Company’s 2015 Stock Incentive Plan (the “Plan”). Any capitalized term not defined herein shall have the same meaning ascribed to it in the Plan.
STOCK PURCHASE AGREEMENTStock Purchase Agreement • April 18th, 2018 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of the 16th day of April 2018 (the “Effective Date”) by and between AXIM BIOTECHNOLOGIES, INC., a Nevada corporation (the “Company”), and Cross & Company, a Nevada corporation (the “Purchaser”).
CONVERTIBLE NOTE PURCHASE AGREEMENTConvertible Note Purchase Agreement • December 28th, 2023 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
This Convertible Note Purchase Agreement (this "Agreement') is made and entered into as of December 26, 2023 (the "Effective Date") by and among AXIM Biotechnologies, Inc., a Nevada corporation (the "Company"), and Medical Marijuana, Inc., an Oregon corporation (the "Purchaser").
Convertible Note Modification and Default Waiver AgreementConvertible Note Modification and Default Waiver Agreement • January 27th, 2023 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
This Convertible Note Modification and Default Waiver Agreement (the "Agreement") is entered into as of January 23, 2023 (the "Effective Date") by and between Medical Marijuana, Inc., an Oregon corporation ("Creditor") and Axim Biotechnologies, Inc., a Nevada corporation ("AXIM" or the "Company"), with reference to the following facts.
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENTStock Purchase Agreement • December 17th, 2019 • Axim Biotechnologies, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT (this “Amendment”) is made as of the 16th day of December 2019 (the “Effective Date”) by and between Axim Biotechnologies, Inc., a Nevada corporation (the “Company”), and Cross & Company, a Nevada corporation (the “Purchaser”).
DEBT EXCHANGE AGREEMENTDebt Exchange Agreement • December 7th, 2018 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • Utah
This Debt Exchange Agreement (the “Agreement”) is entered into as of November 28, 2018 (the “Effective Date”) by and between Axim Biotechnologies, Inc., a Nevada corporation (the “Company”), and Atlas Sciences, LLC, a Utah limited liability company (“Atlas”), with reference to the following facts:
License And Distribution AgreementLicense and Distribution Agreement • September 19th, 2022 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • Delaware
This License and Distribution Agreement (this “Agreement”) is made on September 15, 2022 (the “Effective Date”) by and between Axim Biotechnologies, Inc. (“Licensor”), a Nevada corporation, and Verséa Ophthalmics, LLC, a Delaware limited liability company (“Licensee”).
CONVERTIBLE NOTEAxim Biotechnologies, Inc. • February 16th, 2022 • Pharmaceutical preparations • California
FOR VALUE RECEIVED, the undersigned, Axim Biotechnologies, Inc., a Nevada corporation (“Debtor”), promises to pay to the order of [INVESTOR], [], or order (“Holder”), at the corporate offices of Holder, or such other place as Holder may designate in writing, the principal amount of [AMOUNT EQUAL TO FACE VALUE] and 00/100 Dollars ($_______), together with interest on the unpaid principal balance from time to time outstanding, computed on the basis of a three hundred sixty (360) day year and compounded on a yearly basis at a rate equal to Three Percent (3%) per annum (the “Interest Rate”).
CONSULTING AGREEMENTConsulting Agreement • May 25th, 2023 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
THIS CONSULTING AGREEMENT (this "Agreement") with an effective date of 23 May 2023 (the "Effective Date"), is made and entered into by and between Accalle, LLC (the "Consultant"), having an office address at 6914 Magellan Way, Sarasota, Florida 34243 and AXIM Biotechnologies, Inc. having an office at 6191 Cornerstone Court, E., Suite 114, San Diego, CA 92121 (the "Company"), (collectively “the parties”).
CONVERTIBLE NOTE PURCHASE AGREEMENTConvertible Note Purchase Agreement • March 21st, 2024 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
This Convertible Note Purchase Agreement (the “Agreement”) is entered into as of March 15, 2024 (the “Effective Date”) by and between [ ] (“Purchaser”), and AXIM Biotechnologies, Inc., a Nevada corporation (“Issuer”), with reference to the following facts:
BINDING TERM SHEETBinding Term Sheet • April 19th, 2022 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
This BINDING TERM SHEET (the "Agreement"), dated as of July 29, 2021, is entered into by and between AXIM Biotechnologies Inc., ("AXIM"), a Nevada Corporation, and Advanced Tear Diagnostics, LLC., a Delaware Limited Liability Company ("ATD") .
SETTLEMENT AGREEMENTSettlement Agreement • January 27th, 2023 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
This Settlement Agreement (the “Agreement”) is entered into as of January 23, 2023 (the “Effective Date”) by and between Axim Biotechnologies, Inc. ("AXIM" or the "Company") and John W. Huemoeller II (the "Executive"), with reference to the following facts:
AXIM Biotechnologies, Inc. New York, NY 10022Letter Agreement • May 23rd, 2016 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • New York
On behalf of AXIM Biotechnologies, Inc. (the “Company”), we are pleased to confirm your employment in the position of Chief Technology Officer pursuant to the terms and conditions of this Letter Agreement (the “Agreement”), effective as of January 1, 2016, and, subject to paragraph number 7 of this Agreement, continuing for an initial term of one (1) year (the “Initial Term”), and thereafter until this Agreement is terminated by either you or the Company.
STOCK PURCHASE AGREEMENTStock Purchase Agreement • March 10th, 2011 • Axim International Inc.
WHEREAS the Company is desirous of allotting and issuing Shares to the Founder, on favourable terms, in exchange for debt incurred by the Founder in getting the Company incorporated and development of a business concept and plan, to enable the Company for public listing subsequently.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 21st, 2024 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
This Stock Purchase Agreement (the “Agreement”) is entered into as of March 15, 2024 (the “Effective Date”) by and between [ ] (“Purchaser”), and AXIM Biotechnologies, Inc., a Nevada corporation (“Issuer”), with reference to the following facts:
TERMINATION AGREEMENTTermination Agreement • April 19th, 2022 • Axim Biotechnologies, Inc. • Pharmaceutical preparations
This Termination Agreement made as of March 3, 2022 (the "Effective Date") by and between AXIM Biotechnologies Inc., a Nevada corporation ("AXIM"), and Empowered Diagnostics LLC, a Florida limited liability Company ("Empowered Diagnostics"), who agree to the following, including the Recitals.
PREFERRED STOCK PURCHASE AGREEMENTPreferred Stock Purchase Agreement • February 26th, 2019 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
This Preferred Stock Purchase Agreement (the “Agreement”) is entered into as of February 20, 2019 (the “Effective Date”) by and between MJNA Investment Holdings, LLC, a Nevada limited liability company (“Seller”), and Juniper & Ivy Corporation, a Nevada corporation (“Purchaser”), with reference to the following facts:
STOCK PURCHASE AGREEMENTStock Purchase Agreement • August 29th, 2022 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of the 23rd day of July, 2022 (the “Effective Date”) by and between AXIM BIOTECHNOLOGIES, INC., a Nevada corporation (the “Company”), and VERSEA HOLDINGS INC, (the “Purchaser”).
STOCK PURCHASE AGREEMENTStock Purchase Agreement • August 29th, 2022 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is effective as of the 1st day of August 24, 2022 (the “Effective Date”) and is made by and between AXIM BIOTECHNOLOGIES, INC., a Nevada corporation (the “Company”), and Catalina Valencia, (the “Purchaser”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • April 19th, 2022 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
ASSET PURCHASE AGREEMENT (the "Asset Purchase Agreement" or "Agreement") made as of August 26, 2021, by and between and ADVANCED TEAR DIAGNOSTICS, LLC a Delaware Limited Liability Company (the "Seller" or "ATD") and AXIM BIOTECHNOLOGIES, INC., a Delaware corporation, (the "Buyer" or "AXIM").
CONVERTIBLE NOTEConvertible Note • May 30th, 2023 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
FOR VALUE RECEIVED, the undersigned, Axim Biotechnologies, Inc., a Nevada corporation (“Debtor”), promises to pay to the order of [__________________________], a [______________________], or order (“Holder”), at the corporate offices of Holder, or such other place as Holder may designate in writing, the principal amount of [______________________________________________________] and 00/100 Dollars ($________), together with interest on the unpaid principal balance from time to time outstanding, computed on the basis of a three hundred sixty (360) day year and compounded on a yearly basis at a rate equal to Three and Three Quarter Percent (3.75%) per annum (the “Interest Rate”).
Convertible Notes Modification and Default Waiver AgreementConvertible Notes Modification and Default Waiver Agreement • January 27th, 2023 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
This Convertible Notes Modification and Default Waiver Agreement (the "Agreement") is entered into as of January 23, 2023 (the "Effective Date") by and between TL-66 LLC, a California limited liability company ("Creditor") and Axim Biotechnologies, Inc., a Nevada corporation ("AXIM" or the "Company") and Sapphire Biotechnologies, Inc, a Delaware corporation, wholly owned subsidiary of AXIM ("Sapphire"), with reference to the following facts.
